Reina Haque to Neoplasm Recurrence, Local
This is a "connection" page, showing publications Reina Haque has written about Neoplasm Recurrence, Local.
Connection Strength
2.173
-
Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen. Breast Cancer Res Treat. 2016 Apr; 156(2):379-89.
Score: 0.460
-
Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors. J Natl Cancer Inst. 2016 Mar; 108(3).
Score: 0.451
-
Long-term safety of radiotherapy and breast cancer laterality in older survivors. Cancer Epidemiol Biomarkers Prev. 2011 Oct; 20(10):2120-6.
Score: 0.336
-
The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Gu?rin in Treating Nonmuscle-Invasive Bladder Cancer. J Urol. 2024 Sep; 212(3):420-430.
Score: 0.203
-
Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol. 2017 06; 197(6):1448-1454.
Score: 0.121
-
Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case-Control Study. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S502-8.
Score: 0.109
-
A hybrid approach to identify subsequent breast cancer using pathology and automated health information data. Med Care. 2015 Apr; 53(4):380-5.
Score: 0.108
-
Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst. 2012 Apr 18; 104(8):614-21.
Score: 0.087
-
Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol. 2009 Dec; 33(12):1802-8.
Score: 0.074
-
Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009; 11(6):R85.
Score: 0.074
-
Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomarkers Prev. 2009 Nov; 18(11):2979-83.
Score: 0.074
-
Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. Breast Cancer Res Treat. 2015 Dec; 154(3):609-16.
Score: 0.028
-
Fracture risk in older, long-term survivors of early-stage breast cancer. J Am Geriatr Soc. 2013 Jun; 61(6):888-95.
Score: 0.024
-
Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013 Jun; 139(2):453-60.
Score: 0.024